EllumGet notified

BPC-157 / GHK-Cu stack: what's in it

By Ellum EditorialUpdated AI use

The short answer

BPC-157 / GHK-Cu stack combines BPC-157 and GHK-Cu.

The parts

  • BPC-157 Index

    Not FDA-approved · advisory vote July 2026 · no FDA decision

    WADA 2026: S0

    Papers on animals103
    Lab-dish (cell) papers1
    Papers PubMed tags as about people55
    Registered trials (ClinicalTrials.gov)2 of 3 search results name BPC-157
    Randomized trials in peoplenone found

  • GHK-Cu (injectable) Index

    Not FDA-approved

Bars are counts of papers or trials; a longer bar means more studies, not better results. Study counts auto-counted from PubMed tags and ClinicalTrials.gov in the Ellum research database, as of October 6, 2026 (not reviewed; a paper can carry more than one tag). Papers PubMed tags as about people: includes reviews and case reports; not randomized trials. All bars share one scale. Each count is for that part alone.

What studies found

The study findings below come from our BPC-157 page. They are not a review of GHK-Cu or the combination.

Studies of BPC-157 found effects in cells and in rats: in a dish, rat tendon cells moved and spread faster, and in rats, cut Achilles tendons regained strength and alkali skin burns closed sooner.[1][2][3]

In rat tendon cells, BPC-157 switched on FAK-paxillin, a signal linked to cell movement. The same kind of cells made more growth hormone receptor.[1][4] In human blood-vessel cells and rats, BPC-157 acted through VEGFR2, a vessel-growth receptor, and nitric oxide.[5][6]

In rats with a surgically cut Achilles tendon, the BPC-157 group showed a higher load to failure, better walking-function scores and smaller tendon defects than controls.[2] In a rat model of alkali skin burns, wounds closed faster and showed more collagen and new tissue at day 18 than in controls.[3] In rats, BPC-157 was linked to healing of chemically induced colitis and of a bowel join, and to less nerve damage in a toxic model used to study multiple sclerosis. These are measured outcomes in animal models, not results in patients.[7][8]

A 2019 review said most BPC-157 studies used small rodents and that results in humans were yet to be confirmed. A registered trial is a plan, not a finding.[8] Who did the research matters. A 2019 review of soft-tissue studies noted that only a handful of research groups had studied BPC-157 in depth, that most studies used small rodents and that efficacy in humans was yet to be confirmed.[8] Many reviews come from the group that first described the peptide, including reviews of its stomach origin, its ties to nitric oxide and its comparison with growth factors.[9][10][11]

Key point

Most findings on BPC-157 come from rats and cells, and no human trial has posted results yet.[8][12][13]

Safety

The safety notes below come from our BPC-157 page. They are not a safety review of GHK-Cu or the combination.

BPC-157 has two registered Phase 1 trials with a safety aim, one in healthy volunteers and a pilot after rotator cuff surgery, and neither has posted results.[12][13] A 2019 review found few studies reporting adverse reactions, but most studies were in small rodents.[8] Long-term safety in people is unknown. Products marketed 'for research use' aren't made to drug-quality standards.[8][12]

BPC-157 safety detail comes from animal and lab work, and much of it from the group that first described the peptide.[10][9] Rat and lab studies found effects on blood vessels and blood clotting that remain open questions for people.[6][14][15][16] In isolated rat aorta, BPC-157 relaxed the vessel through nitric oxide, and the effect grew as the concentration rose.[6] In rats, BPC-157 changed blood-pressure responses to drugs that block or feed nitric oxide production, without changing normal blood pressure.[14] In rats given aspirin, clopidogrel or cilostazol, BPC-157 largely reversed those drugs' effect on platelet clumping.[15] In other rat studies, BPC-157 reduced bleeding time after tail amputation, including in rats given heparin, warfarin or aspirin.[16] Whether these effects occur in people who take blood thinners has not been reported in a human trial.[8][12]

BPC-157 promoted new blood-vessel growth in chick embryo membranes and in rats.[5] A review from the originating group notes that new vessel growth is also part of tumor biology.[17] The cited animal studies did not test tumor growth.[5][17] A lack of reported side effects in rats does not show that BPC-157 is harmless in people.[8]

Key point

Long-term effects of BPC-157 in humans are unknown, and no human trial has posted results.[8][12][13]

Regulatory status by component

Not FDA-approved How we label status

  • As of October 4, 2026, BPC-157 is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See BPC-157 in the Index →
  • As of October 4, 2026, GHK-Cu (injectable) is not FDA-approved for any use and is not on FDA's 503A bulks list. See GHK-Cu (injectable) in the Index →

Status as of October 4, 2026

As a combination
No category as a combination (see components)
  • BPC-157: as of October 4, 2026 · source
  • GHK-Cu (injectable): as of October 4, 2026 · source

Get updates on BPC-157 / GHK-Cu stack

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: BPC-157 / GHK-Cu stack (1 selected) · edit
Peptides you're interested in
What we may email you about
More options (optional): research, doctor contact, paid offers

The research on BPC-157 / GHK-Cu stack

Key facts

Also known as: bpc ghk-cu, bpc-157 ghk-cu

Parts
BPC-157 and GHK-Cu (injectable)
Route
injectable;oral

References

  1. pubmed.ncbi.nlm.nih.gov/21030672
  2. pubmed.ncbi.nlm.nih.gov/14554208
  3. pubmed.ncbi.nlm.nih.gov/25995620
  4. pubmed.ncbi.nlm.nih.gov/25415472
  5. pubmed.ncbi.nlm.nih.gov/27847966
  6. pubmed.ncbi.nlm.nih.gov/33051481
  7. pubmed.ncbi.nlm.nih.gov/24304574
  8. pubmed.ncbi.nlm.nih.gov/30915550
  9. pubmed.ncbi.nlm.nih.gov/22950504
  10. pubmed.ncbi.nlm.nih.gov/23755725
  11. pubmed.ncbi.nlm.nih.gov/29998800
  12. clinicaltrials.gov/study/NCT02637284
  13. clinicaltrials.gov/study/NCT07803250
  14. pubmed.ncbi.nlm.nih.gov/9298922
  15. pubmed.ncbi.nlm.nih.gov/31976029
  16. pubmed.ncbi.nlm.nih.gov/21840572
  17. pubmed.ncbi.nlm.nih.gov/23782145
  18. pubmed.ncbi.nlm.nih.gov/9403788

Status sources

Sources as of October 4, 2026

  1. FDA: www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  2. FDA: www.fda.gov/media/94155/download

What this doesn’t establish

Results for one compound don't tell you what the two do together.

The BPC-157 evidence does not establish that any effect seen in rats, chickens or lab cells happens in people.[8][18] A 2019 review states that efficacy is yet to be confirmed in humans, so no benefit for any condition in people has been shown.[8] Amounts used in rats do not translate to people. Most of the research comes from a handful of groups, which limits independent confirmation.[8]